Literature DB >> 7819214

Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators.

D F Tang-Wai1, S Kajiji, F DiCapua, D de Graaf, I B Roninson, P Gros.   

Abstract

Possible functional differences between P-glycoproteins (P-gps) encoded by the human MDR1 and mouse mdr1 and mdr3 genes with respect to drug resistance profiles and sensitivity to known modulators have been investigated. For this, the three genes were introduced and overexpressed in the same cellular background, that of Chinese hamster LR73 ovary cells, and drug-resistant clones expressing comparable amounts of the corresponding P-gps were selected under the same conditions. Analysis of the specific drug resistance profiles encoded by each P-gp for colchicine, adriamycin, vinblastine, and actinomycin D revealed overlapping but distinct patterns of drug resistance for the three isoforms. While all three P-gps conferred levels of resistance to vinblastine that did not vary by more than 2.5-fold, each isoform could be clearly distinguished by its capacity to confer resistance to colchicine and actinomycin D. Likewise, the study of structurally related and unrelated P-gp modulators indicated strong isoform-specific differences in the capacity of individual modulators to abrogate vinblastine resistance in the corresponding mdr transfectants. The study of several disubstituted piperazine analogs indicated that minor chemical modifications of the linker region of this modulator had strong effects on the sensitivity profile of each isoform to the modulator. Together, these results indicate that the three P-gp isoforms analyzed have specific and distinguishable functional characteristics with respect to interactions with drugs and modulators. These findings also suggest that P-gp positive murine transplantable tumors should be used with caution in the design and in vivo testing of novel P-gp modulators to be used to reverse multidrug resistance to tumor cells expressing human MDR1.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7819214     DOI: 10.1021/bi00001a005

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  24 in total

1.  The enantioselective binding of mefloquine enantiomers to P-glycoprotein determined using an immobilized P-glycoprotein liquid chromatographic stationary phase.

Authors:  L Lu; F Leonessa; M T Baynham; R Clarke; F Gimenez; Y T Pham; F Roux; I W Wainer
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

2.  Stereoselective transport of hydrophilic quaternary drugs by human MDR1 and rat Mdr1b P-glycoproteins.

Authors:  Guido J E J Hooiveld; Janette Heegsma; Jessica E van Montfoort; Peter L M Jansen; Dirk K F Meijer; Michael Müller
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

Review 3.  Oral delivery of taxanes.

Authors:  M M Malingré; J H Beijnen; J H Schellens
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

4.  Natural variation in human membrane transporter genes reveals evolutionary and functional constraints.

Authors:  Maya K Leabman; Conrad C Huang; Joseph DeYoung; Elaine J Carlson; Travis R Taylor; Melanie de la Cruz; Susan J Johns; Doug Stryke; Michiko Kawamoto; Thomas J Urban; Deanna L Kroetz; Thomas E Ferrin; Andrew G Clark; Neil Risch; Ira Herskowitz; Kathleen M Giacomini
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-28       Impact factor: 11.205

Review 5.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1.

Authors:  Toshiyuki Takeuchi; Sumie Yoshitomi; Tomoaki Higuchi; Keiko Ikemoto; Shin-ichi Niwa; Takuya Ebihara; Miki Katoh; Tsuyoshi Yokoi; Satoru Asahi
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

7.  The ATPase activity of the P-glycoprotein drug pump is highly activated when the N-terminal and central regions of the nucleotide-binding domains are linked closely together.

Authors:  Tip W Loo; M Claire Bartlett; Michael R Detty; David M Clarke
Journal:  J Biol Chem       Date:  2012-06-14       Impact factor: 5.157

8.  Bioimaging real-time PXR-dependent mdr1a gene regulation in mdr1a.fLUC reporter mice.

Authors:  Long Gu; Jasmine Chen; Timothy W Synold; Barry M Forman; Susan E Kane
Journal:  J Pharmacol Exp Ther       Date:  2013-03-26       Impact factor: 4.030

9.  Structure of a multidrug transporter.

Authors:  Michael M Gottesman; Suresh V Ambudkar; Di Xia
Journal:  Nat Biotechnol       Date:  2009-06       Impact factor: 54.908

10.  A new model for studying tissue-specific mdr1a gene expression in vivo by live imaging.

Authors:  Long Gu; Walter M Tsark; Donna A Brown; Suzette Blanchard; Timothy W Synold; Susan E Kane
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.